Anavex Life Sciences Corp

Anavex Life Sciences Corp a clinical stage biopharmaceutical company engages in the development of drug candidates for the treatment of central nervous system CNS diseases Its lead drug candidate is ANAVEX 273 which is in Phase III clinical trial for the treatment of Alzheimers disease Phase III clinical trial to treat pediatric patients with Rett syndrome Phase II clinical trial for the treatment of Parkinsons disease and preclinical clinical trials to treat epilepsy infantile spasms Fragile X syndrome Angelman syndrome multiple sclerosis and tuberous sclerosis complex The companys drug candidate also comprises ANAVEX 371 which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications and preclinical clinical trials for the treatment of neurodegenerative diseases such as Alzheimers and Parkinsons diseases Its preclinical drug candidates include ANAVEX 141 a sigma1 receptor agonist for the treatment of depression stroke Parkinsons and Alzheimers diseases ANAVEX 1066 a mixed sigma1sigma2 ligand for the potential treatment of neuropathic and visceral pain and ANAVEX 1037 to treat prostate and pancreatic cancer The company was incorporated in 2004 and is headquartered in New York New York